NCT05288543 - A Study of Orally Administered IPG7236 in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

October 30, 2022

Study Completion Date

December 31, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

IPG7236- Single ascending dose

Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state

DRUG

IPG7236- Multiple ascending dose

Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state

OTHER

Placebo (Part A)

Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state

Trial Locations (1)

RECRUITING

Scientia Clinical Research Ltd, Randwick

All Listed Sponsors

collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Nanjing Immunophage Biotech Co., Ltd

INDUSTRY